INTEGRATED DRUG CREATION
LIVE

Serial Number

99656789

Owner

Absci Corporation

Attorney

Tiffany D. Gehrke

Filing Date

Feb 17, 2026

Add to watchlist:

No watchlists yet
View on USPTO

INTEGRATED DRUG CREATION Trademark

Serial Number: 99656789

INTEGRATED DRUG CREATION is a trademark filed by Absci Corporation on February 17, 2026. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Absci Corporation

18105 SE Mill Plain Blvd.
Vancouver, WA 98683

Entity Type: 03

Trademark Details

Filing Date

February 17, 2026

Registration Date

Not Registered

Goods & Services

Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; discovery of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation relating to the production of biotechnological products for use in preparing pharmaceutical preparations; Bioinformatics research services, namely, analyzing complex biological data through the use of artificial intelligence, and testing and evaluation of biologics through artificial intelligence; computer assisted biologics design involving the use of artificial intelligence technology; Biotechnological services, namely, discovery of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, discovery of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments

Biotechnological services, namely, custom production and purification of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, custom production of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments

Filing History

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 18, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 18, 2026 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 25, 2026 GNRN
NON-FINAL ACTION E-MAILED
Mar 25, 2026 GNRT
NON-FINAL ACTION WRITTEN
Mar 25, 2026 CNRT
ASSIGNED TO EXAMINER
Mar 23, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 17, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 17, 2026 NWOS
NEW APPLICATION ENTERED
Feb 17, 2026 NWAP